Duloxetine Capsule, Delayed Release
Product Images NDC 70518-1244

Product Visual Gallery

This gallery contains 12 technical images submitted to the FDA as part of the official labeling for Duloxetine (NDC 70518-1244). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

7ad45dfa A630 4e5f 85c0 25dc9e8bfbb7 01

Chemical structure of duloxetine hydrochloride showing its molecular framework with a naphthalene ring, oxygen, sulfur-containing thiophene ring, and an amine group associated with hydrochloride.*

FDA Label Image

7ad45dfa A630 4e5f 85c0 25dc9e8bfbb7 02

A Kaplan-Meier estimator graph depicting the proportion of patients with relapse over time in days for Duloxetine versus placebo. The x-axis represents time from randomization to relapse, ranging from 0 to 250 days, and the y-axis represents the proportion of patients with relapse, ranging from 0 to 1. Duloxetine is shown with a solid line, and placebo with a dashed line, illustrating relapse rates over time.*

FDA Label Image

7ad45dfa A630 4e5f 85c0 25dc9e8bfbb7 03

Kaplan-Meier curve graph depicting the proportion of patients with relapse over time (days) from randomization for Duloxetine compared to placebo. The graph shows relapse rates on the y-axis and days on the x-axis, with Duloxetine represented by a solid line and placebo by a dashed line.*

FDA Label Image

7ad45dfa A630 4e5f 85c0 25dc9e8bfbb7 04

A line graph depicting the percentage of patients improved versus the percent improvement in pain from baseline. The graph compares four groups: Duloxetine 60 mg twice daily, Duloxetine 60 mg once daily, Duloxetine 20 mg once daily, and placebo. Each group shows a decreasing trend in patient improvement as the percent improvement in pain increases, with the placebo group generally having the lowest percentage of patients improved.*

FDA Label Image

7ad45dfa A630 4e5f 85c0 25dc9e8bfbb7 05

A line graph illustrating the percentage of patients improved versus percent improvement in pain from baseline. It compares three groups: Duloxetine 60 mg twice daily (BID), Duloxetine 60 mg once daily (QD), and placebo, showing patient improvement trends across different levels of pain improvement.*

FDA Label Image

7ad45dfa A630 4e5f 85c0 25dc9e8bfbb7 06

A line graph depicting the percentage of patients improved versus percent improvement in pain from baseline. It compares Duloxetine 60 mg taken twice daily, Duloxetine 60 mg once daily, and placebo groups, showing higher pain improvement percentages for Duloxetine groups across the range.*

FDA Label Image

7ad45dfa A630 4e5f 85c0 25dc9e8bfbb7 07

A line graph showing the percentage of patients improved on the y-axis against the percent improvement in pain from baseline on the x-axis. The graph compares four groups: Duloxetine 120 mg twice daily, Duloxetine 60 mg once daily (two lines, one solid and one dashed), and placebo. All lines show a trend of decreasing patient improvement percentage as the percent improvement in pain increases.*

FDA Label Image

7ad45dfa A630 4e5f 85c0 25dc9e8bfbb7 08

A line graph showing the percentage of pediatric patients aged 13 to 17 with juvenile fibromyalgia syndrome achieving various levels of pain relief at week 12. The graph compares Duloxetine 60mg once daily to placebo by percent improvement in pain from baseline on the x-axis, with the percentage of patients improved on the y-axis. Two data lines illustrate higher pain relief percentages for Duloxetine compared to placebo across multiple thresholds of improvement.*

FDA Label Image

7ad45dfa A630 4e5f 85c0 25dc9e8bfbb7 09

A line graph comparing the percentage of patients improved versus percent improvement in pain from baseline for Duloxetine 60/120 mg once daily and placebo. The x-axis shows percent improvement in pain (BOCF), and the y-axis shows the percentage of patients improved. Two curves demonstrate patient improvement at different pain improvement thresholds for the two treatments.*

FDA Label Image

7ad45dfa A630 4e5f 85c0 25dc9e8bfbb7 10

A line graph comparing the percentage of patients improved versus percent improvement in pain from baseline (BOCF) for Duloxetine 60 mg once daily and placebo groups. The x-axis shows percent improvement intervals from greater than 0 to 100%, and the y-axis shows the percentage of patients improved from 0 to 100%. Duloxetine consistently shows a higher percentage of patients improved across pain improvement intervals compared to placebo.*

FDA Label Image

7ad45dfa A630 4e5f 85c0 25dc9e8bfbb7 11

A line graph comparing the percentage of patients improved versus the percent improvement in pain from baseline (BOCF) for Duloxetine 60/120 mg once daily and placebo. The graph shows two lines, one with diamond markers for Duloxetine and one with cross markers for placebo, illustrating patient improvement trends across pain improvement levels from >0% to 100%.*

FDA Label Image

Remedy_label (Remedy Label)

Label for Duloxetine 60 mg delayed-release capsules, quantity of 60 capsules per container. The label includes drug name, strength, dosage form, and manufacturer details showing it is repackaged by RemedyRepack Inc. with original manufacturing by Lupin Pharma. It features dosing caveats and storage instructions.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.